CD1A Antibody

What is CD1A and where is it expressed in human tissues?

CD1A is a non-classical MHC class I-like glycoprotein of 43-49 kDa that is non-covalently associated with β2-microglobulin, which appears necessary for efficient folding and surface expression . It functions as an antigen-presenting protein that binds self and non-self lipid and glycolipid antigens, presenting them to T-cell receptors on natural killer T-cells .

CD1A is primarily expressed on:

• Cortical thymocytes

• Epidermal Langerhans cells

• Dendritic cells (particularly in skin)

• Certain T-cell leukemias

• Subsets of cells in nasal mucosa, lungs, gut, conjunctiva, and cervix

In skin specifically, CD1A is highly expressed by cutaneous mononuclear phagocytes such as Langerhans cells and subsets of dermal dendritic cells . Expression can also be induced on innate lymphoid cells type 2 (ILC2s) and BDCA-2+ skin-infiltrating dendritic cells in response to cytokines and other mediators .

How does the structure of CD1A differ from other CD1 family members?

CD1A belongs to the CD1 family which consists of five isoforms (CD1a-e) subclassified into three different groups:

• Group 1: CD1a, CD1b, CD1c - involved in lipid antigen presentation, expressed primarily on APCs and thymocytes

• Group 2: CD1d - involved in lipid antigen presentation, expressed on hematopoietic and epithelial cells

• CD1e: involved in lipid processing and loading rather than antigen presentation

CD1A has a unique antigen-binding cleft consisting of two pockets (A′ and F′):

• The F′ pocket connects to the extracellular environment via the F′ tunnel, permitting antigen loading

• The roofed A′ pocket regulates antigen size, accommodating lipids with acyl chains containing 32–42 carbons

This structure allows CD1A to sample a broad range of ligands and drive immune responses. Recent advances in lipid identification have shown remarkable patterns of shared and unique molecular species across CD1 isoforms .

What are the key epitopes and post-translational modifications of CD1A?

CD1A can be serologically defined by four different epitopes, designated as groups A, B, C, and D. Cross-inhibition studies with different monoclonal antibodies have revealed that:

• Epitopes A, C, and D are distinct

• Epitope B overlaps with epitopes A and C

Post-translational modifications of CD1A include glycosylation . In humans, the canonical protein has a reported length of 327 amino acid residues and a mass of 37.1 kDa . CD1A molecules are internalized following antibody binding, similar to MHC I molecules .

What are the recommended applications for different types of CD1A antibodies?

CD1A antibodies are widely used in multiple research applications, with specific recommendations based on antibody type:

Flow cytometry (FCM) and immunohistochemistry (IHC) are the most common applications . Clone MTB1 may detect small focal groups of lymphocytes outside the germinal centers of tonsil, indicating a cross-reaction with CD1b antigen .

How should CD1A antibodies be validated for experimental research?

Proper validation of CD1A antibodies should include:

• Specificity testing: Verify the antibody recognizes CD1A specifically by using:

  • Positive controls: Test on cell lines known to express CD1A (T-ALL cell lines)

  • Negative controls: Test on cells lacking CD1A expression

  • Cross-reactivity assessment: Check for potential cross-reactions with other CD1 family members, particularly CD1b

• Functional validation:

  • Internalization assays: Confirm that the CD1A-antibody complex is internalized at 37°C using confocal microscopy

  • Effector function testing: Evaluate complement-dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC) activity against CD1A expressing cell lines

• Application-specific validation:

  • For IHC: Test on tissues with known CD1A distribution (thymus, skin, tonsil)

  • For flow cytometry: Establish appropriate gating strategies using relevant cell populations

High-quality antibodies like CR2113 (a human anti-CD1A mAb) show high specificity and avidity against cells expressing CD1 antigen variants .

What are the technical considerations for using CD1A antibodies in flow cytometry?

When using CD1A antibodies for flow cytometry, researchers should consider:

• Sample preparation:

  • For blood samples: Use appropriate lysing solutions to remove red blood cells

  • For tissue samples: Generate single-cell suspensions while maintaining CD1A expression

  • Cell fixation can affect epitope accessibility; optimize fixation conditions

• Antibody selection and panel design:

  • Choose appropriate fluorophores based on instrument configuration

  • Include markers to identify specific cell populations (dendritic cells, Langerhans cells)

  • Consider additional markers such as langerin (CD207) which assists CD1A antigen loading

• Controls and analysis:

  • Include isotype controls to assess non-specific binding

  • Use FMO (Fluorescence Minus One) controls for proper gating

  • Consider analyzing CD1A in conjunction with other markers to identify specific cell subsets

  • Quantify both percentage positive and median fluorescence intensity

• Potential pitfalls:

  • CD1A expression can be dynamic and change with cell activation status

  • Expression may be induced on certain cell types by cytokines and other mediators

  • Some antibody clones may cross-react with CD1b

How is CD1A involved in Langerhans Cell Histiocytosis and T-cell leukemias?

CD1A serves as an important marker and potential therapeutic target in these diseases:

Langerhans Cell Histiocytosis (LCH):

• CD1A is highly expressed on Langerhans cells, the pathological cell type in LCH

• CD1A antibodies can be used for diagnostic purposes to identify these cells

• Therapeutic potential: Monoclonal antibodies like CR2113 show promise for clinical diagnostic imaging and therapeutic targeting of LCH

T-cell Acute Lymphoblastic Leukemia (T-ALL):

• CD1A is expressed on the cortical subtype of T-ALL

• CD1A antibodies like CR2113 recognize CD1A in T-ALL cell lines and patient samples

• Therapeutic applications:

  • CR2113 induces moderate complement-dependent cytotoxicity (CDC)

  • Potent antibody-dependent cell cytotoxicity (ADCC) activity observed against CD1A-expressing T-ALL cell lines and patient samples

  • In vivo experiments show CR2113 as a naked antibody has modest but specific anti-tumor activity against CD1A-expressing tumors

These findings suggest CD1A antibodies have potential both for diagnostic purposes and as therapeutic agents in these malignancies.

What is the role of CD1A in inflammatory skin diseases?

CD1A plays significant roles in several inflammatory skin conditions:

Psoriasis:

• CD1A-dependent mechanisms contribute to pathology

• CD1A-reactive T cells may produce inflammatory cytokines that contribute to disease

Atopic Dermatitis (AD):

• CD1A has been implicated in AD pathogenesis

• CD1A-reactive T cells may contribute to cutaneous inflammation

Allergic Contact Dermatitis (ACD):

• CD1A-dependent mechanisms are directly involved in ACD development

• Allergens such as urushiol (poison ivy) directly induce CD1A-dependent T-cell responses

• Using a human CD1a transgenic mouse model, researchers discovered skin inflammation was driven by urushiol-specific CD1a-dependent CD4+ T cells secreting IL-17 and IL-22

• Additional CD1A contact dermatitis allergens include farnesol, benzyl benzoate, benzyl cinnamate, and coenzyme Q compounds

• These allergens do not require cellular processing prior to CD1A loading

In graft versus host disease, immunohistochemical studies have reported a reduction in epidermal Langerhans cells . CD1A-positive dendritic cells also participate in atherosclerotic lesion formation and asthmatic inflammation .

How do CD1A-reactive T cells function in immune responses?

CD1A-reactive T cells demonstrate several key characteristics in immune function:

• Distribution and recruitment:

  • Found within peripheral blood

  • Can be recruited into skin through cutaneous homing receptors (CLA, CCR4, CCR6, and CCR10)

  • Present at higher frequencies in blood than conventional MHC-restricted T cells

• Antigen recognition:

  • Unlike conventional MHC-restricted T cells, CD1A-reactive T-cell responses aren't always limited to specific CD1A-lipid combinations

  • Different lipid antigens may serve as universal CD1A ligands

  • Recognize both endogenous lipids and exogenous lipids (including bacterial components)

• Function in defense:

  • Present mycobacterial-derived antigens like dideoxymycobactin and lysyl-phosphatidylglycerol (lysyl-PG) from gram-positive bacteria

  • Contribute to host pathogen defenses

  • Contribution to mycobacterium tuberculosis recognition demonstrated using a group 1 CD1 transgenic mouse model

• Cytokine production and phenotype:

  • Can produce a diverse panel of cytokines

  • Contribute to cutaneous inflammation under certain circumstances

  • Mostly express αβ TCR, but subsets can express γδ TCR

  • May express either CD4 or CD8 co-receptor

This versatility in antigen recognition and cytokine production positions CD1A-reactive T cells as important components of both protective immunity and pathological inflammation.

How do different lipid antigens interact with the CD1A binding groove?

CD1A has unique interactions with various lipid antigens that make it distinct from other CD1 family members:

• Lipid acquisition mechanisms:

  • Captures lipids at multiple locations:

    • At the cell surface

    • During translocation through the endoplasmic reticulum and Golgi secretory pathway

    • Following internalization into the early endosomal pathway

  • This allows CD1A to sample a broad range of ligands and drive diverse immune responses

• Structural determinants of binding:

  • Unique antigen-binding cleft with two pockets (A′ and F′)

  • The F′ pocket connects to the extracellular environment via F′ tunnel for antigen loading

  • The roofed A′ pocket regulates antigen size, accommodating lipids with acyl chains containing 32–42 carbons

  • Selectivity partially mediated by these structural features

• Specific lipid interactions:

  • Endogenous skin lipids: Wax esters, squalene, fatty acids, sphingomyelins, sulfatides, and triacylglycerides serve as continuous pool of CD1A antigens

  • Urushiol (poison ivy allergen): Can displace ganglioside GD3 from the CD1A cleft, with approximately 20% of the urushiol molecule extending outside the cleft

  • Farnesol: Can reside deeply within the CD1A cleft, adopting a medial alignment

  • Mycobacterial lipids: Dideoxymycobactin and other unique lipids

Recent advances in identification and quantitation of lipids eluted from CD1 isoforms have revealed remarkable patterns of shared and unique molecular species that will inform future analyses and disease associations .

What are the challenges in engineering CD1A-based immunotherapeutic approaches?

Developing CD1A-based immunotherapeutics faces several challenges that researchers must address:

• Antibody design considerations:

  • Specificity: Ensuring antibodies target CD1A without cross-reactivity to other CD1 family members

  • Functional activity: Optimizing CDC and ADCC activities (CR2113 showed moderate CDC but potent ADCC)

  • Internalization properties: CD1A-antibody complexes are internalized at 37°C, which could be exploited for antibody-drug conjugates

• Targeting strategy optimization:

  • Naked antibodies: CR2113 showed modest but specific anti-tumor activity against CD1A-expressing tumors in vivo

  • Antibody modifications: Engineering Fc regions for enhanced effector functions

  • Drug conjugation: Exploiting internalization for targeted delivery

  • Bispecific antibodies: Linking CD1A targeting with T cell engagement

• Target expression considerations:

  • Heterogeneity of CD1A expression within tumors

  • Expression on normal tissues (Langerhans cells, thymocytes) may lead to on-target, off-tumor effects

  • Potential for modulating CD1A expression to enhance therapeutic window

• Clinical development challenges:

  • Animal model limitations: Species differences in CD1A expression and function

  • Need for specialized in vivo models (like hCD1a-Tg transgenic mice)

  • Biomarker development for patient selection

  • Combination strategies with existing therapies

The high-affinity human anti-CD1A mAb CR2113 with significant ADCC activity represents a promising candidate for clinical diagnostic imaging and therapeutic targeting of LCH and potentially other CD1A-positive malignancies .

How can CD1A transgenic mouse models advance our understanding of CD1A biology?

CD1A transgenic mouse models provide valuable tools for studying CD1A biology that cannot be addressed in conventional models:

• Key advantages of CD1A transgenic models:

  • Enable the study of human CD1A functions in vivo

  • Allow manipulation of genetic background and environmental factors

  • Facilitate preclinical testing of CD1A-targeted therapies

  • Permit detailed analysis of CD1A-restricted T cell responses

• Research applications:

  • Infectious disease: Contribution of CD1A in mycobacterium tuberculosis recognition demonstrated using a group 1 CD1 transgenic mouse model

  • Contact dermatitis: hCD1a-Tg mouse model revealed that skin inflammation was driven by urushiol-specific CD1a-dependent CD4+ T cells secreting IL-17 and IL-22, corresponding to the cytokine changes observed in humans with poison ivy dermatitis

  • Cancer immunotherapy: Evaluation of CD1A antibody efficacy (e.g., CR2113) against CD1A-expressing tumors

• Methodological considerations:

  • Expression pattern control: Ensuring CD1A expression patterns match human tissue distribution

  • T cell repertoire development: Generating mice with human T cell receptors that recognize CD1A-lipid complexes

  • Lipid environment: Accounting for differences in murine vs. human lipid profiles

• Limitations and solutions:

  • Species differences in lipid metabolism

  • Variations in innate immune system components

  • Need for humanized immune components in some studies

  • Potential for complementary in vitro human systems

These models are particularly valuable for studying conditions where CD1A plays a significant role, such as contact dermatitis and infectious diseases, and for evaluating potential therapeutic interventions.

How should researchers optimize immunohistochemistry protocols for CD1A detection?

Optimizing immunohistochemistry (IHC) protocols for CD1A detection requires attention to several critical factors:

• Sample preparation:

  • Fixation: Formalin fixation is commonly used, but overfixation may mask epitopes

  • Antigen retrieval methods: Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Section thickness: 4-5 μm sections are typically optimal for CD1A detection

• Antibody selection and optimization:

  • Clone selection: Clone MTB1 detects cortical thymocytes, Langerhans cells in epidermis, interdigitating cells of dermis, and interdigitating cells of stratified squamous epithelium of tonsil

  • Titration: Determine optimal antibody concentration using positive control tissues

  • Incubation conditions: Time, temperature, and buffer composition should be optimized

• Detection system selection:

  • Polymer-based detection systems often provide better sensitivity than biotin-avidin systems

  • Chromogen selection: DAB (brown) is most common, but AEC (red) may provide better contrast in certain tissues

  • Counterstaining: Adjust hematoxylin intensity to maintain visibility of CD1A staining

• Controls and validation:

  • Positive tissue controls: Thymus, tonsil, and normal skin are excellent positive controls

  • Negative controls: Include isotype controls and antibody diluent-only controls

  • Be aware that Clone MTB1 may detect small focal groups of lymphocytes outside the germinal centers of tonsil indicating a cross-reaction with CD1b antigen

• Troubleshooting common issues:

  • Weak staining: Increase antibody concentration, extend incubation time, or optimize antigen retrieval

  • Background staining: Increase blocking, reduce antibody concentration, or modify washing steps

  • False negatives: Ensure proper tissue fixation, storage, and processing

What considerations are important when analyzing CD1A in complex tissue microenvironments?

Analyzing CD1A in complex tissue microenvironments presents unique challenges:

• Multicellular context analysis:

  • Use multiplex immunofluorescence or immunohistochemistry to simultaneously visualize CD1A with other markers

  • Consider co-staining with:

    • Langerin (CD207) for Langerhans cells identification

    • Dendritic cell markers (CD11c, HLA-DR)

    • T cell markers to study CD1A-T cell interactions

    • Inflammatory markers in disease states

• Spatial relationship assessment:

  • Quantify CD1A+ cell distribution within different tissue compartments

  • Analyze proximity of CD1A+ cells to other immune cells

  • In skin, assess changes in epidermal vs. dermal distribution in different conditions

  • Consider digital pathology approaches for quantitative spatial analysis

• Functional correlations:

  • Link CD1A expression patterns to clinical parameters

  • Correlate CD1A+ cell density with disease activity markers

  • Studies have shown reduction in epidermal Langerhans cells in graft versus host disease

  • CD1A+ dendritic cells participate in atherosclerotic lesion formation and asthmatic inflammation

• Technical considerations:

  • Tissue processing effects: Lipids critical for CD1A function may be lost during standard processing

  • Specialized fixation methods may be needed for certain applications

  • Serial sections may be required for comprehensive analysis

  • Consider in situ hybridization for CD1A mRNA to complement protein detection

• Quantification approaches:

  • Cell counting strategies: Manual vs. automated image analysis

  • Expression intensity measurement: Consider both positive cell percentage and staining intensity

  • Morphological features: Assess changes in CD1A+ cell morphology in different conditions

What are the best practices for isolating and analyzing CD1A-reactive T cells?

Isolating and analyzing CD1A-reactive T cells requires specialized approaches:

• Isolation strategies:

  • Direct isolation using CD1A tetramers loaded with relevant lipid antigens

  • Functional isolation based on cytokine production in response to CD1A-expressing APCs

  • Expansion from blood or tissue using CD1A-expressing feeder cells

  • Consider that CD1A-reactive T cells are found within peripheral blood and can be recruited into skin through cutaneous homing receptors (CLA, CCR4, CCR6, and CCR10)

• Phenotypic characterization:

  • TCR analysis: CD1A-reactive T cells mostly express αβ TCR, but subsets can express γδ TCR

  • Co-receptor expression: May express either CD4 or CD8

  • Tissue homing markers: Assess expression of skin-homing receptors

  • Memory/naive phenotyping: Determine differentiation state

• Functional analysis:

  • Cytokine profiling: CD1A-reactive T cells can produce diverse cytokines including IL-17 and IL-22

  • Cytotoxicity assays against CD1A-expressing targets

  • Proliferation in response to CD1A-presented lipid antigens

  • Migration assays to assess tissue-homing potential

• Antigen specificity testing:

  • Test responses to endogenous lipids (wax esters, squalene, fatty acids, sphingomyelins, sulfatides, triacylglycerides)

  • Assess recognition of exogenous lipids (e.g., urushiol, farnesol, benzyl benzoate)

  • Determine cross-reactivity patterns across different CD1A-presented lipids

  • Note that unlike conventional MHC-restricted T cells, CD1A-reactive T-cell responses may not always be limited to specific CD1A-lipid combinations

• Advanced analytical approaches:

  • Single-cell RNA sequencing to identify transcriptional profiles

  • TCR sequencing to assess clonal diversity and expansion

  • Integration with tissue imaging data for comprehensive understanding

  • Correlation with clinical parameters in disease states

These methodological considerations facilitate rigorous investigation of CD1A-reactive T cells and their roles in both homeostasis and disease.